Loading...

Natasha Martin

Title(s)Associate Professor, Medicine
SchoolHealth Sciences
Phone858-822-4802
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Oxford University, Oxford, UKDPhil/PhD2009Mathematical biology
    Stanford University, Palo Alto, CABS2003Mathematics, biology
    Collapse Awards and Honors
    2016Selected by The Economist Magazine as an "HCV Changemaker"

    Collapse Overview 
    Collapse Overview
    Dr. Natasha Martin is an infectious disease economic modeler who develops dynamic transmission models to evaluate the impact and cost-effectiveness of public health interventions. She is currently an Associate Professor in the Division of Infectious Diseases and Global Public Health at the University of California San Diego and holds an honorary senior lecturer position at the University of Bristol. She is also the co-director of the Biostatistics and Modeling Core of the University of California San Diego Center for AIDS Research (UCSD CFAR). She has worked for 18 years developing mathematical models of disease progression and transmission in both communicable and non-communicable diseases. For the past eight years, her primary research has focused on modeling hepatitis C virus (HCV) and HIV transmission and prevention among high-risk groups such as people who inject drugs (PWID), men who have sex with men, and female sex workers. She is a leading researcher on modeling the impact of HCV treatment as prevention. Additionally, she has experience developing dynamic cost-effectiveness evaluations of case-finding and prevention interventions, and has the only published cost-effectiveness models of HCV case-finding interventions and treatment including both individual and population benefits. She is the principal investigator (PI) of a NIAID/NIDA-funded R01 optimizing HIV and HCV prevention portfolios among people who inject drugs in 108 countries. Her modeling work informed the WHO guidelines “When to start ART in people living with HIV (2013)”, and her work on the impact and cost-effectiveness of HCV treatment among people who inject drugs informed the WHO guidelines on “Hepatitis C testing, care, and treatment (2013)”. More recently, her modeling work on HCV elimination was used to inform the WHO “Global Health Sector Strategy on Viral Hepatitis 2016-2021”.

    Collapse Research 
    Collapse Research Activities and Funding
    Optimizing HIV prevention portfolios targeting people who inject drugs using dynamic economic modeling
    NIH/NIAID R01AI147490Aug 7, 2019 - Jul 31, 2023
    Role: Principal Investigator
    University of California, San Diego, Center for AIDS Research
    NIH 5 P30 AI036214Apr 1, 2018 - Mar 31, 2023
    Role: Co-Director, Biostatistics and Modeling Core
    Modeling Structural HIV Determinants in Substance Users and related populations
    NIH/NIDA R01DA037773Apr 1, 2015 - Dec 31, 2017
    Role: Principal Investigator
    Modeling opioid overdose and prevention in Australia
    Australian NHMRC Dec 31, 2023
    Role: Co-I
    Evaluating the Population Impact of Hepatitis C Direct Acting Antiviral Treatment as Prevention for People Who Inject Drugs (EPIToPe).
    UK National Institute for Health Research Feb 1, 2023
    Role: Co-investigator
    HCV elimination among men who have sex with men in Germany
    Gilead Jun 1, 2022
    Role: Co-investigator
    Impact of direct acting antivirals uptake in controlling hepatitis C epidemic and modeling interventions for hepatitis C elimination among HIV-infected persons in San Diego
    Gilead Jan 1, 2021
    Role: Co-PI
    Modeling HCV elimination among HIV-infected men who have sex with men and people who inject drugs
    Gilead Dec 31, 2020
    Role: Principal Investigator
    Testing and comparing study designs for evaluating HCV treatment as prevention (TasP) impact in a real world setting
    Merck Dec 1, 2020
    Role: Principal Investigator
    Texting intervention to sustain HIV prevention in women in high-drug-use contexts
    NIH/NIDA Jun 1, 2020
    Role: Co-investigator
    Cost-effectiveness of HCV testing and treatment in pregnant women
    Gilead Apr 30, 2020
    Role: Principal Investigator
    Surveillance and Treatment of Prisoners with hepatitis C (STOP-C)
    Australian NHMRC Dec 31, 2019
    Role: Co-Investigator
    Role Description: To test HCV treatment as prevention among prisoners in New South Wales, Australia. Overseeing modeling to inform trial design, implementation and evaluation.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Marquez LK, Cepeda JA, Bórquez A, Strathdee SA, Gonzalez-Zúñiga PE, Fleiz C, Rafful C, Garfein RS, Kiene SM, Brodine S, Martin NK. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. Int J Drug Policy. 2020 Mar 09; 102710. PMID: 32165050.
      View in: PubMed
    2. Lim AG, Walker JG, Mafirakureva N, Khalid GG, Qureshi H, Mahmood H, Trickey A, Fraser H, Aslam K, Falq G, Fortas C, Zahid H, Naveed A, Auat R, Saeed Q, Davies CF, Mukandavire C, Glass N, Maman D, Martin NK, Hickman M, May MT, Hamid S, Loarec A, Averhoff F, Vickerman P. Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis. Lancet Glob Health. 2020 Mar; 8(3):e440-e450. PMID: 32087176.
      View in: PubMed
    3. Martin NK, Hickman M, Spaulding AC, Vickerman P. Prisons can also improve drug user health in the community. Addiction. 2020 Feb 05. PMID: 32026531.
      View in: PubMed
    4. Ward Z, Reynolds R, Campbell L, Martin NK, Harrison G, Irving W, Hickman M, Vickerman P. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England. Addiction. 2020 Jan 26. PMID: 31984606.
      View in: PubMed
    5. Macgregor L, Desai M, Martin NK, Nicholls J, Hickson F, Weatherburn P, Hickman M, Vickerman P. Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxis. EClinicalMedicine. 2020 Feb; 19:100217. PMID: 32140664.
      View in: PubMed
    6. Walker JG, Kuchuloria T, Sergeenko D, Fraser H, Lim AG, Shadaker S, Hagan L, Gamkrelidze A, Kvaratskhelia V, Gvinjilia L, Aladashvili M, Asatiani A, Baliashvili D, Butsashvili M, Chikovani I, Khonelidze I, Kirtadze I, Kuniholm MH, Otiashvili D, Sharvadze L, Stvilia K, Tsertsvadze T, Zakalashvili M, Hickman M, Martin NK, Morgan J, Nasrullah M, Averhoff F, Vickerman P. Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. Lancet Glob Health. 2020 Feb; 8(2):e244-e253. PMID: 31864917.
      View in: PubMed
    7. Marks C, Borquez A, Jain S, Sun X, Strathdee SA, Garfein RS, Milloy MJ, DeBeck K, Cepeda JA, Werb D, Martin NK. Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis. PLoS Med. 2019 11; 16(11):e1002973. PMID: 31770373.
      View in: PubMed
    8. Chaillon A, Rand EB, Reau N, Martin NK. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019 Nov 13; 69(11):1888-1895. PMID: 30689769.
      View in: PubMed
    9. Farrell M, Martin NK, Stockings E, Bórquez A, Cepeda JA, Degenhardt L, Ali R, Tran LT, Rehm J, Torrens M, Shoptaw S, McKetin R. Responding to global stimulant use: challenges and opportunities. Lancet. 2019 11 02; 394(10209):1652-1667. PMID: 31668409.
      View in: PubMed
    10. Martin NK, Jansen K, An der Heiden M, Boesecke C, Boyd A, Schewe K, Baumgarten A, Lutz T, Christensen S, Thielen A, Mauss S, Rockstroh JK, Skaathun B, Ingiliz P. Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis. J Infect Dis. 2019 Oct 08; 220(10):1635-1644. PMID: 31301142.
      View in: PubMed
    11. Trickey A, Fraser H, Lim AG, Walker JG, Peacock A, Colledge S, Leung J, Grebely J, Larney S, Martin NK, Degenhardt L, Hickman M, May MT, Vickerman P. Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. J Viral Hepat. 2019 Dec; 26(12):1388-1403. PMID: 31392812.
      View in: PubMed
    12. Fraser H, Vellozzi C, Hoerger TJ, Evans JL, Kral AH, Havens J, Young AM, Stone J, Handanagic S, Hariri S, Barbosa C, Hickman M, Leib A, Martin NK, Nerlander L, Raymond HF, Page K, Zibbell J, Ward JW, Vickerman P. Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison. Am J Epidemiol. 2019 Aug 01; 188(8):1539-1551. PMID: 31150044.
      View in: PubMed
    13. Martin NK, Vickerman P, Khakoo S, Ghosh A, Ramsay M, Hickman M, Williams J, Miners A. Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation. BMJ Open. 2019 06 28; 9(6):e030183. PMID: 31256040.
      View in: PubMed
    14. Chaillon A, Mehta SR, Hoenigl M, Solomon SS, Vickerman P, Hickman M, Skaathun B, Martin NK. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One. 2019; 14(6):e0217964. PMID: 31170246.
      View in: PubMed
    15. Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, Leung J, Grebely J, Larney S, Martin NK, Hickman M, Degenhardt L, May MT, Vickerman P. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019 Jun; 4(6):435-444. PMID: 30981685.
      View in: PubMed
    16. Chaillon A, Sun X, Cachay ER, Looney D, Wyles D, Garfein RS, Martin TCS, Jain S, Mehta SR, Smith DM, Little SJ, Martin NK. Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000-2015. Open Forum Infect Dis. 2019 Apr; 6(4):ofz160. PMID: 31041355.
      View in: PubMed
    17. Cepeda JA, Burgos JL, Kahn JG, Padilla R, Meza Martinez PE, Segovia LA, Gaines T, Abramovitz D, Rangel G, Magis-Rodriguez C, Vickerman P, Strathdee SA, Martin NK. Evaluating the impact of global fund withdrawal on needle and syringe provision, cost and use among people who inject drugs in Tijuana, Mexico: a costing analysis. BMJ Open. 2019 01 29; 9(1):e026298. PMID: 30700490.
      View in: PubMed
    18. Pitcher AB, Borquez A, Skaathun B, Martin NK. Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies. J Theor Biol. 2019 Nov 21; 481:194-201. PMID: 30452959.
      View in: PubMed
    19. Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, Trickey A, Abbott S, Strathdee SA, Abramovitz D, Maher L, Iversen J, Bruneau J, Zang G, Garfein RS, Yen YF, Azim T, Mehta SH, Milloy MJ, Hellard ME, Sacks-Davis R, Dietze PM, Aitken C, Aladashvili M, Tsertsvadze T, Mravcík V, Alary M, Roy E, Smyrnov P, Sazonova Y, Young AM, Havens JR, Hope VD, Desai M, Heinsbroek E, Hutchinson SJ, Palmateer NE, McAuley A, Platt L, Martin NK, Altice FL, Hickman M, Vickerman P. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2018 12; 18(12):1397-1409. PMID: 30385157.
      View in: PubMed
    20. Garfein RS, Liu L, Cuevas-Mota J, Collins K, Muñoz F, Catanzaro DG, Moser K, Higashi J, Al-Samarrai T, Kriner P, Vaishampayan J, Cepeda J, Bulterys MA, Martin NK, Rios P, Raab F. Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA. Emerg Infect Dis. 2018 10; 24(10):1806-1815. PMID: 30226154.
      View in: PubMed
    21. Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int. 2019 01; 39(1):20-30. PMID: 30157316.
      View in: PubMed
    22. Borquez A, Beletsky L, Nosyk B, Strathdee SA, Madrazo A, Abramovitz D, Rafful C, Morales M, Cepeda J, Panagiotoglou D, Krebs E, Vickerman P, Claude Boily M, Thomson N, Martin NK. The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. Lancet Public Health. 2018 09; 3(9):e429-e437. PMID: 30122559.
      View in: PubMed
    23. Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A, Hakim J, Havlir D, Isbell MT, Johnson L, Kamarulzaman A, Kasaie P, Kazatchkine M, Kilonzo N, Klag M, Klein M, Lewin SR, Luo C, Makofane K, Martin NK, Mayer K, Millett G, Ntusi N, Pace L, Pike C, Piot P, Pozniak A, Quinn TC, Rockstroh J, Ratevosian J, Ryan O, Sippel S, Spire B, Soucat A, Starrs A, Strathdee SA, Thomson N, Vella S, Schechter M, Vickerman P, Weir B, Beyrer C. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission. Lancet. 2018 07 28; 392(10144):312-358. PMID: 30032975.
      View in: PubMed
    24. Cepeda JA, Eritsyan K, Vickerman P, Lyubimova A, Shegay M, Odinokova V, Beletsky L, Borquez A, Hickman M, Beyrer C, Martin NK. Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. Lancet HIV. 2018 10; 5(10):e578-e587. PMID: 30033374.
      View in: PubMed
    25. Fraser H, Mukandavire C, Martin NK, Goldberg D, Palmateer N, Munro A, Taylor A, Hickman M, Hutchinson S, Vickerman P. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. Addiction. 2018 11; 113(11):2118-2131. PMID: 29781207.
      View in: PubMed
    26. Martin TCS, Rauch A, Salazar-Vizcaya L, Martin NK. Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men. Infect Dis Clin North Am. 2018 06; 32(2):395-405. PMID: 29778262.
      View in: PubMed
    27. Burgos JL, Cepeda JA, Kahn JG, Mittal ML, Meza E, Lazos RRP, Vargas PC, Vickerman P, Strathdee SA, Martin NK. Cost of provision of opioid substitution therapy provision in Tijuana, Mexico. Harm Reduct J. 2018 05 23; 15(1):28. PMID: 29792191.
      View in: PubMed
    28. Lim AG, Qureshi H, Mahmood H, Hamid S, Davies CF, Trickey A, Glass N, Saeed Q, Fraser H, Walker JG, Mukandavire C, Hickman M, Martin NK, May MT, Averhoff F, Vickerman P. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. Int J Epidemiol. 2018 04 01; 47(2):550-560. PMID: 29309592.
      View in: PubMed
    29. Martin NK, Boerekamps A, Hill AM, Rijnders BJA. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it? J Int AIDS Soc. 2018 04; 21 Suppl 2:e25062. PMID: 29633560.
      View in: PubMed
    30. Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Maticic M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol. 2018 03; 68(3):402-411. PMID: 29080808.
      View in: PubMed
    31. MacGregor L, Martin NK, Mukandavire C, Hickson F, Weatherburn P, Hickman M, Vickerman P. Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact. Int J Epidemiol. 2017 10 01; 46(5):1582-1592. PMID: 28605503.
      View in: PubMed
    32. Fraser H, Zibbell J, Hoerger T, Hariri S, Vellozzi C, Martin NK, Kral AH, Hickman M, Ward JW, Vickerman P. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic. Addiction. 2018 Jan; 113(1):173-182. PMID: 28734093.
      View in: PubMed
    33. Martin NK, Skaathun B, Vickerman P, Stuart D. Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs. AIDS Rev. 2017 Apr - Jun; 19(2):97-104. PMID: 28534885.
      View in: PubMed
    34. Fraser H, Mukandavire C, Martin NK, Hickman M, Cohen MS, Miller WC, Vickerman P. HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidence. Int J Epidemiol. 2017 04 01; 46(2):466-478. PMID: 27524816.
      View in: PubMed
    35. Martin NK, Vickerman P, Hickman M. How to eliminate HCV infection by antiviral treatment. J Hepatol. 2017 07; 67(1):5-6. PMID: 28323120.
      View in: PubMed
    36. Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, Munro A, Dunleavy K, Peters E, Bramley P, Hayes PC, Goldberg DJ, Vickerman P. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction. 2017 Jul; 112(7):1302-1314. PMID: 28257600.
      View in: PubMed
    37. Higgins JP, Soares-Weiser K, López-López JA, Kakourou A, Chaplin K, Christensen H, Martin NK, Sterne JA, Reingold AL. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016 Oct 13; 355:i5170. PMID: 27737834.
      View in: PubMed
    38. Aspinall EJ, Mitchell W, Schofield J, Cairns A, Lamond S, Bramley P, Peters SE, Valerio H, Tomnay J, Goldberg DJ, Mills PR, Barclay ST, Fraser A, Dillon JF, Martin NK, Hickman M, Hutchinson SJ. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat. 2016 12; 23(12):1009-1016. PMID: 27509844.
      View in: PubMed
    39. Hickman M, Martin NK, Huxtable R. Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs. Addiction. 2017 02; 112(2):201-203. PMID: 27514647.
      View in: PubMed
    40. Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, Taxman FS, El-Bassel N, Martin NK, Booth R, Stöver H, Dolan K, Vickerman P. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016 Sep 17; 388(10050):1228-48. PMID: 27427455.
      View in: PubMed
    41. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016 Sep 10; 388(10049):1081-1088. PMID: 27394647.
      View in: PubMed
    42. Martin NK, Vickerman P, Hickman M. Reply. Hepatology. 2016 11; 64(5):1822-1823. PMID: 27112633.
      View in: PubMed
    43. Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? PLoS One. 2016; 11(5):e0156213. PMID: 27224423.
      View in: PubMed
    44. Martin NK, Vickerman P, Hickman M, Patterson TL, Rand E, Abramovitz D, Strathdee SA. Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV prevention. Addiction. 2016 09; 111(9):1512-5. PMID: 27075692.
      View in: PubMed
    45. Harris RJ, Martin NK, Rand E, Mandal S, Mutimer D, Vickerman P, Ramsay ME, De Angelis D, Hickman M, Harris HE. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat. 2016 08; 23(8):631-43. PMID: 27025238.
      View in: PubMed
    46. Martin NK, Vickerman P, Brew IF, Williamson J, Miners A, Irving WL, Saksena S, Hutchinson SJ, Mandal S, O'Moore E, Hickman M. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology. 2016 06; 63(6):1796-808. PMID: 26864802.
      View in: PubMed
    47. Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, Martin TCS, Delpech V, Ruf M, Price H, Azad Y, Thomson EC, Vickerman P. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clin Infect Dis. 2016 May 01; 62(9):1072-1080. PMID: 26908813.
      View in: PubMed
    48. Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, Foster GR, Hutchinson SJ, Goldberg DJ, Martin TCS, Ramsay M, Hickman M. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol. 2016 07; 65(1):17-25. PMID: 26867489.
      View in: PubMed
    49. Geue C, Wu O, Xin Y, Heggie R, Hutchinson S, Martin NK, Fenwick E, Goldberg D. Cost-Effectiveness of HBV and HCV Screening Strategies--A Systematic Review of Existing Modelling Techniques. PLoS One. 2015; 10(12):e0145022. PMID: 26689908.
      View in: PubMed
    50. Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis. 2015 Dec; 28(6):576-82. PMID: 26524330.
      View in: PubMed
    51. Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS. 2015 Sep; 10(5):374-80. PMID: 26248124.
      View in: PubMed
    52. Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med. 2015 Aug 20; 13:198. PMID: 26289050.
      View in: PubMed
    53. Pines HA, Patterson TL, Rangel G, Martinez G, Bazzi AR, Ulibarri MD, Syvertsen JL, Martin NK, Strathdee SA. STI/HIV test result disclosure between female sex workers and their primary, non-commercial male partners in two Mexico-US border cities: a prospective study. Sex Transm Infect. 2015 May; 91(3):207-13. PMID: 25298381.
      View in: PubMed
    54. Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat. 2015 Apr; 22(4):399-408. PMID: 25288193.
      View in: PubMed
    55. Panovska-Griffiths J, Vassall A, Prudden HJ, Lépine A, Boily MC, Chandrashekar S, Mitchell KM, Beattie TS, Alary M, Martin NK, Vickerman P. Optimal allocation of resources in female sex worker targeted HIV prevention interventions: model insights from Avahan in South India. PLoS One. 2014; 9(10):e107066. PMID: 25271808.
      View in: PubMed
    56. McGillen JB, Kelly CJ, Martínez-González A, Martin NK, Gaffney EA, Maini PK, Pérez-García VM. Glucose-lactate metabolic cooperation in cancer: insights from a spatial mathematical model and implications for targeted therapy. J Theor Biol. 2014 Nov 21; 361:190-203. PMID: 25264268.
      View in: PubMed
    57. Martin NK, Vickerman P, Goldberg D, Hickman M. HCV treatment as prevention in prison: key issues. Hepatology. 2015 Jan; 61(1):402-3. PMID: 24797358.
      View in: PubMed
    58. Martin NK, Devine A, Eaton JW, Miners A, Hallett TB, Foster GR, Dore GJ, Easterbrook PJ, Legood R, Vickerman P. Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa. AIDS. 2014 Jan; 28 Suppl 1:S35-46. PMID: 24468945.
      View in: PubMed
    59. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2013 Dec 10; 2(1):23-34. PMID: 25083415.
      View in: PubMed
    60. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2014 Jan; 2(1):e23-34. PMID: 25104632.
      View in: PubMed
    61. Miners AH, Martin NK, Ghosh A, Hickman M, Vickerman P. Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. J Viral Hepat. 2014; 21(9):616-23. PMID: 24215210.
      View in: PubMed
    62. Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, Gazzard BG, Nelson M. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS. 2013 Oct 23; 27(16):2551-7. PMID: 23736152.
      View in: PubMed
    63. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, Hickman M. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013 Nov; 58(5):1598-609. PMID: 23553643.
      View in: PubMed
    64. Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open. 2013 Aug 13; 3(8). PMID: 23943776.
      View in: PubMed
    65. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013 Aug; 57 Suppl 2:S39-45. PMID: 23884064.
      View in: PubMed
    66. Martin TC, Martin NK, Naresh KN, Nelson M. Atraumatic splenic rupture secondary to chronic HIV infection. Int J STD AIDS. 2013 Dec; 24(12):989-91. PMID: 23970617.
      View in: PubMed
    67. Martin NK, Vickerman P, Miners A, Hickman M. How cost-effective is hepatitis C virus treatment for people who inject drugs? J Gastroenterol Hepatol. 2013 Apr; 28(4):590-2. PMID: 23527756.
      View in: PubMed
    68. McGillen JB, Gaffney EA, Martin NK, Maini PK. A general reaction-diffusion model of acidity in cancer invasion. J Math Biol. 2014 Apr; 68(5):1199-224. PMID: 23536240.
      View in: PubMed
    69. Vickerman P, Martin NK, Roy A, Beattie T, Jarlais DD, Strathdee S, Wiessing L, Hickman M. Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Depend. 2013 Sep 01; 132(1-2):172-81. PMID: 23453261.
      View in: PubMed
    70. Farne HA, Martin NK, Main J, Orchard T, Tyrrell-Price J. C-reactive protein is a useful predictor of metronidazole treatment failure in mild-to-moderate Clostridium difficile infection. Eur J Gastroenterol Hepatol. 2013 Jan; 25(1):33-6. PMID: 23026925.
      View in: PubMed
    71. Vickerman P, Martin NK, Hickman M. Could low dead-space syringes really reduce HIV transmission to low levels? Int J Drug Policy. 2013 Jan; 24(1):8-14. PMID: 23206493.
      View in: PubMed
    72. Martin TC, Scourfield A, Rockwood N, Martin NK, Patel N, Nelson M, Gazzard BG. Pancreatic insufficiency in patients with HIV infection: role of didanosine questioned. HIV Med. 2013 Mar; 14(3):161-6. PMID: 22994793.
      View in: PubMed
    73. Hellard ME, Jenkinson R, Higgs P, Stoové MA, Sacks-Davis R, Gold J, Hickman M, Vickerman P, Martin NK. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust. 2012 Jun 04; 196(10):638-41. PMID: 22676879.
      View in: PubMed
    74. Martin NK, Robey IF, Gaffney EA, Gillies RJ, Gatenby RA, Maini PK. Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study. Br J Cancer. 2012 Mar 27; 106(7):1280-7. PMID: 22382688.
      View in: PubMed
    75. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012 Jan; 55(1):49-57. PMID: 21898506.
      View in: PubMed
    76. Vickerman P, Martin NK, Hickman M. Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings--implications for intervention impact. Drug Alcohol Depend. 2012 Jun 01; 123(1-3):122-31. PMID: 22138540.
      View in: PubMed
    77. Martin NK, Pitcher AB, Vickerman P, Vassall A, Hickman M. Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One. 2011; 6(8):e22309. PMID: 21853030.
      View in: PubMed
    78. Robey IF, Martin NK. Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer. BMC Cancer. 2011 Jun 10; 11:235. PMID: 21663677.
      View in: PubMed
    79. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011 Jun; 54(6):1137-44. PMID: 21145810.
      View in: PubMed
    80. Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol. 2011 Apr 07; 274(1):58-66. PMID: 21236265.
      View in: PubMed
    81. Martin NK, Gaffney EA, Gatenby RA, Gillies RJ, Robey IF, Maini PK. A mathematical model of tumour and blood pHe regulation: The HCO3-/CO2 buffering system. Math Biosci. 2011 Mar; 230(1):1-11. PMID: 21167185.
      View in: PubMed
    82. Martin NK, Gaffney EA, Gatenby RA, Maini PK. Tumour-stromal interactions in acid-mediated invasion: a mathematical model. J Theor Biol. 2010 Dec 07; 267(3):461-70. PMID: 20816684.
      View in: PubMed
    83. Martin NK, Gaffney EA, Gatenby RA, Maini PK. Leaky vessels as a potential source of stromal acidification in tumours. J Theor Biol. 2010 Dec 07; 267(3):454-60. PMID: 20699102.
      View in: PubMed
    Natasha's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (258) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (27) people
    _
    Similar People
    People who share similar concepts with this person.
    See all (60) people
    _
    Same Department
    Search Department
    ↑